Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00398047 · OUTCOME

Minor Hematological Improvements

Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes · Source last updated 2018-09-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Approximately 112 days

What was measured

For patients with pretreatment platelet count less than 100,000/mm3, a 50% or more increase in platelet count with a net increase greater than 10,000/mm3 but less than 30,000/mm3

Analysis population: Because no patients completed therapy, no analysis was possible

Groups in this outcome

Azacitidine and Darbopoietin and G-CSF

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Azacitidine and Darbopoietin and G-CSF0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
For patients with pretreatment platelet count less than 100,000/mm3, a 50% or more increase in platelet count with a net increase greater than 10,000/mm3 but less than 30,000/mm3
groups
  1. id
    OG000
    title
    Azacitidine and Darbopoietin and G-CSF
population Description
Because no patients completed therapy, no analysis was possible
reporting Status
POSTED
time Frame
Approximately 112 days
title
Minor Hematological Improvements
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice